Loading...
Statins are known to raise risk for diabetes modestly. In this meta-analysis of individual participant data from 23 randomized statin trials, researchers estimated the incidence of this adverse effect. Findings were as follows:
The incidence of new-onset diabetes was only slightly (but statistically significantly) higher with low-to-moderate–intensity statins compared with placebo (1.3% vs. 1.2% annually).
In contrast to the small effect with low-to-moderate–intensity statin, risk for new-onset diabetes was more substantial with high-intensity statins compared with placebo (4.8% vs. 3.5% annually).
New-onset diabetes was diagnosed more often in patients with baseline glycosylated hemoglobin (HbA1c) in the prediabetes range than in patients wit…